Stacking GLP-1s with Other Drugs: Metformin, Phentermine, or Contrave?

You've been on a Affordable GLP-1 medication for months. The weight is coming off—but slower than you hoped. Or maybe you've hit a frustrating plateau. Or perhaps you're one of the estimated 20% of people who simply don't respond well to GLP-1s alone

Now you're wondering: Can I take something else with it?

The short answer is yes. A strategy called "stacking"—combining GLP-1s with other weight loss medications—is gaining traction among obesity specialists. But not all combinations are created equal, and each comes with its own risks and benefits.

This article breaks down the three most common stacking options: Metformin, Phentermine (often with topiramate), and Contrave (naltrexone/bupropion). You'll learn how each works, what the evidence says, and whether stacking might be right for you.

Why Stack? The Logic Behind Combination Therapy
Obesity is not a simple condition with a single cause. It involves multiple pathways: hunger hormones, reward circuits in the brain, metabolic rate, insulin sensitivity, and more . GLP-1s primarily work by slowing gastric emptying and signaling fullness to the brain. But they don't address every mechanism.

Stacking targets different pathways simultaneously. As one researcher put it, "Combining NB-ER with GLP-1 makes mechanistic sense because GLP-1 primarily makes a person feel full faster and decreases hunger, while NB-ER reduces food cravings" .

Think of it as a multi-pronged attack. If one drug turns down the volume on hunger, another might quiet the specific craving for fatty, sugary foods. Together, they can potentially break through plateaus and help non-responders finally see results.

Stacking Option 1: Metformin
Metformin is the old workhorse of diabetes treatment—an oral medication used for decades to improve insulin sensitivity and lower blood sugar. It's not typically considered a weight loss drug, but it is weight-neutral to mildly weight-reducing.

How It Works
Metformin decreases glucose production in the liver and improves your body's sensitivity to insulin. It doesn't directly suppress appetite like GLP-1s, but by addressing insulin resistance—a common driver of weight gain—it can complement GLP-1 therapy.

The Evidence for Stacking
There is no large-scale trial specifically examining GLP-1 plus metformin for weight loss. However, the combination is standard practice for type 2 diabetes management, and many patients on both medications do experience better glycemic control and modest additional weight loss.

Who Might Benefit
Patients with insulin resistance or prediabetes/diabetes

Those who have plateaued on GLP-1 alone and have stubborn blood sugar issues

Individuals who cannot tolerate higher GLP-1 doses

Risks and Considerations
Metformin is generally very safe, with gastrointestinal side effects (nausea, diarrhea) being the most common. Since GLP-1s also cause GI issues, stacking can amplify these effects. Starting metformin at a low dose and titrating slowly is essential.

Stacking Option 2: Phentermine (with or without Topiramate)
Phentermine is a stimulant-like appetite suppressant, one of the oldest weight loss medications on the market. It's often combined with topiramate (an anticonvulsant) in a branded formulation called Qsymia—a combination that research has shown to be highly effective .

How It Works
Phentermine increases norepinephrine release in the brain, which suppresses appetite and may increase energy expenditure. Topiramate, added in Qsymia, modulates GABA and AMPA receptors to reduce cravings and increase feelings of fullness .

Together, they target different pathways than GLP-1s. While GLP-1s work primarily on the gut-brain axis to induce satiety, phentermine/topiramate works directly on brain chemistry to reduce the desire to eat.

The Evidence for Stacking
Research comparing GLP-1s and phentermine/topiramate head-to-head is limited, but existing data is encouraging.

A real-world study at an urban safety-net clinic compared patients taking GLP-1 analogs (primarily liraglutide) to those taking phentermine/topiramate . After one year:

Medication Median Weight Loss
GLP-1 analog (liraglutide) -3.69 kg (approx 8 lbs)
Phentermine/topiramate -7.01 kg (approx 15.5 lbs)
Lifestyle modification only -3.01 kg (approx 6.6 lbs)
Both medications produced significant weight loss compared to lifestyle alone, and interestingly, phentermine/topiramate actually showed greater weight loss in this study. However, the authors note there was no statistically significant difference between the groups (p=0.11) .

Another meta-analysis from 2024 identified phentermine-topiramate and GLP-1 receptor agonists as the most effective medication classes for facilitating weight loss in adults who are overweight or obese .

Who Might Benefit
Patients who are poor responders to GLP-1s alone (less than 5% weight loss after 6 months)

Those who struggle with constant hunger even on GLP-1s

Individuals without contraindications to stimulants (uncontrolled hypertension, heart disease, glaucoma, hyperthyroidism, or MAOI use)

Risks and Considerations
Phentermine carries significant risks :

Cardiovascular effects: Increased heart rate and blood pressure

Contraindications: Not for use in people with heart disease, uncontrolled hypertension, hyperthyroidism, glaucoma, or history of drug abuse

Side effects: Dry mouth, insomnia, constipation, dizziness

Topiramate adds its own side effect profile: cognitive dysfunction ("brain fog"), paresthesias (tingling in extremities), taste changes, and increased risk of kidney stones .

Important: Phentermine is a controlled substance and is typically prescribed for short-term use (up to 12 weeks), unlike GLP-1s which are intended for long-term chronic treatment. Stacking long-term would be off-label.

Stacking Option 3: Contrave (Naltrexone/Bupropion)
Contrave is a fixed-dose combination of two medications: naltrexone (an opioid antagonist) and bupropion (an antidepressant and smoking cessation aid). It is FDA-approved specifically for chronic weight management .

How It Works
This combination targets the brain's reward system :

Bupropion enhances dopaminergic and noradrenergic activity, increasing energy levels and reducing appetite

Naltrexone blocks mu-opioid receptors, inhibiting the rewarding and reinforcing effects of food consumption

Together, they specifically address hedonic eating—the desire to eat for pleasure rather than hunger. For patients who crave fatty or sugary foods because their brain associates these with pleasure, "Contrave dampens this brain signal and makes eating fatty food or sugary food less satisfying (less pleasurable) and reduces the urge to 'comfort eat' or crave these foods" .

The Evidence for Stacking
This is the most promising and best-studied stacking combination to date.

A recent review published in 2025 made a formal case for combining GLP-1s with Contrave . The rationale: GLP-1s primarily make you feel full faster and decrease hunger (the "homeostatic" pathway), while Contrave reduces food cravings and the pleasure response to food (the "hedonic" pathway). They target different mechanisms, potentially working synergistically.

The review authors suggest this combination may be particularly helpful for:

Patients who struggle with binge eating or impulsive (hedonic) eating

Those who did not achieve at least 5% weight loss with GLP-1 alone

As one researcher noted, "A significant number of patients have suboptimal responses to GLP-1 therapies. This is reason enough for the scientific community to keep investigating ways of finding alternative and adjunctive treatments" .

Additionally, some clinicians are exploring Contrave as a maintenance strategy after stopping GLP-1s—using it to help patients keep weight off at a lower cost .

Who Might Benefit
GLP-1 non-responders (less than 5% weight loss)

Patients with food addiction or binge eating tendencies

Those trying to transition off GLP-1s for cost or side effect reasons

Individuals without contraindications (uncontrolled hypertension, seizure disorders, bulimia/anorexia, chronic opioid use, or MAOI use)

Risks and Considerations
Contrave has its own significant side effect profile :

Nausea, constipation, headache, vomiting, dizziness, dry mouth

Elevated blood pressure and heart rate (requires monitoring)

Risk of seizures (contraindicated in seizure disorders)

Hepatotoxicity (liver damage) — requires monitoring

Boxed warning about increased risk of suicidal thoughts (common to all bupropion products)

The dose titration is also more complex than GLP-1s. The standard initiation is one tablet (90mg bupropion/8mg naltrexone) in the morning for week 1, then increasing to morning and evening thereafter .

Head-to-Head Comparison: Three Stacking Options
Agent Primary Mechanism Typical Weight Loss (alone) Best For Major Risks
Metformin Improves insulin sensitivity 2-3% Insulin-resistant patients GI side effects
Phentermine/topiramate (Qsymia) CNS stimulant + anticonvulsant 10.9% Non-responders to GLP-1s Increased BP/HR, cognitive effects
Contrave (naltrexone/bupropion) Blocks food reward signals 5.4% Hedonic/binge eating Seizure risk, hepatotoxicity
The Future of "Stacking": Built-In Multi-Agonists
Before you rush to stack multiple pills, it's worth noting that the pharmaceutical industry is already ahead of you. Newer GLP-1 "co-agonists" and "tri-agonists" combine multiple hormonal pathways into a single injection .

These include:

Tirzepatide (Zepbound/Mounjaro): A dual GLP-1/GIP agonist achieving up to 22.5% weight loss

CagriSema (under development): Combines semaglutide with cagrilintide (an amylin analog)

Retatrutide (under development): A triple GLP-1/GIP/glucagon agonist

These agents essentially "stack" mechanisms within a single molecule, potentially offering the benefits of combination therapy with a single injection and a simpler safety profile.

Practical Advice: Should You Stack?
Before Stacking, Ask Yourself
Are you truly optimized on your GLP-1? Have you reached the maximum tolerated dose? Have you been on it for at least 6 months? Many patients are labeled "non-responders" too early.

What is the specific barrier? Is it constant hunger (consider phentermine or Contrave)? Blood sugar issues (consider metformin)? Binge eating (consider Contrave)? The right stack depends on the problem.

Do you have contraindications? All three options have significant medical exclusions. A thorough medical evaluation is essential.

Is your insurance onboard? Stacking multiple weight loss medications is often off-label and may not be covered.

If You Decide to Stack
Start low, go slow. Introduce one new medication at a time at the lowest possible dose.

Monitor closely. Track weight, blood pressure, side effects, and mood.

Work with a specialist. This is not a DIY project. An obesity medicine physician or endocrinologist should oversee stacking.

Have an exit plan. If you don't see meaningful improvement after 3 months of stacking, reassess whether the added risk is worth it.

The Bottom Line
Stacking GLP-1s with other weight loss medications is a legitimate, emerging strategy—particularly for patients who are poor responders or who have specific eating patterns (like hedonic or binge eating) that GLP-1s alone don't fully address.

Contrave (naltrexone/bupropion) currently has the strongest mechanistic and clinical rationale for stacking, specifically targeting the brain's reward pathways that GLP-1s largely miss . Phentermine/topiramate is highly effective but carries significant cardiovascular and cognitive risks . Metformin is the safest but least potent option, best reserved for patients with concurrent insulin resistance or diabetes.

But stacking is not for everyone. It adds complexity, cost, and risk. For many patients, simply optimizing their GLP-1 dose or switching to a more potent agent (e.g., from semaglutide to tirzepatide, or from liraglutide to semaglutide) may be a better first step.

As one researcher wisely noted, "Obesity treatment is not a one size fits all; we need to come up with a multi-pronged approach targeting multiple pathways" . Stacking is one tool in that multi-pronged toolkit—but it should be used thoughtfully, under expert guidance, and only when simpler approaches have failed.